PARIS--(BUSINESS WIRE)--Regulatory News: BioAlliance Pharma SA (Paris:BIO), a company dedicated to the treatment and supportive care of cancer and AIDS patients, today announced that Loramyc® has obtained Marketing Authorization in Switzerland for the treatment of oropharyngeal candidiasis in immunocompromised patients (mainly cancer and AIDS patients with oral opportunistic infections).
